Literature DB >> 8744794

The role of calcium in the regulation of invasion and angiogenesis.

R Alessandro1, L Masiero, L A Liotta, E C Kohn.   

Abstract

The complex process of invasion and metastasis is now being dissected at the level of cell-cell and cell-substratum signaling. New tools are being developed to facilitate these studies. These tools include mechanisms for the investigation of cellular actions, such as the identification of agents that can be used to examine the signaling pathways involved in adhesion, proteolysis, motility, and angiogenesis. We have demonstrated that CAI, carboxyamido-triazole, selectively inhibits calcium uptake, stimulated or basal, and thereby modulates the elements involved in invasion and angiogenesis. Through modulation of cellular calcium balance, CAI secondarily inhibits calcium-dependent signaling pathways, such as release of second messengers, protein phosphorylation and gene transcription. We have demonstrated that CAI treatment resulted in inhibition of endothelial cell adhesion, migration, expression of proteolytic enzymes, and vessel formation in vitro and in vivo. The process of endothelial cell adhesion and spreading on extracellular matrix substrata results in an increase in intracellular calcium that can be inhibited by CAI exposure. Furthermore, endothelial cell adhesion and spreading on type IV collagen stimulates the secondary signaling events of tyrosine phosphorylation of focal adhesion kinase (pp125FAK) and autophosphorylation of pp125FAK. CAI treatment of the endothelial cells inhibited cell spreading, and both the induction of pp125FAK phosphorylation and the phosphorylation of exogenous substrates by pp125FAK kinase. These data indicate that regulation of cellular events key in the process of angiogenesis may be modulated by intracellular calcium balance thereby creating a new therapeutic target for anticancer research. CAI is in phase I clinical trial for patients with advanced cancers, yielding plasma concentrations in the in vitro anti-angiogenic range.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8744794

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  7 in total

1.  [Ca2+]i as a potential downregulator of alpha2beta1-integrin-mediated A2058 tumor cell migration to type IV collagen.

Authors:  L Hodgson; C Dong
Journal:  Am J Physiol Cell Physiol       Date:  2001-07       Impact factor: 4.249

Review 2.  Molecular pathology of tumor metastasis III. Target array and combinatorial therapies.

Authors:  József Tímár; Andrea Ladányi; István Peták; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

3.  Expression of fascin in thyroid neoplasms: a novel diagnostic marker.

Authors:  Guang Chen; Fa-Ren Zhang; Jiang Ren; Li-Hua Tao; Zhong-Ying Shen; Zhuo Lv; Shi-Jiang Yu; Bing-Fei Dong; Li-Yan Xu; En-Min Li
Journal:  J Cancer Res Clin Oncol       Date:  2008-03-15       Impact factor: 4.553

4.  Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.

Authors:  G Puppa; P Maisonneuve; A Sonzogni; M Masullo; A Chiappa; M Valerio; M G Zampino; I Franceschetti; P Capelli; M Chilosi; F Menestrina; G Viale; G Pelosi
Journal:  Br J Cancer       Date:  2007-03-20       Impact factor: 7.640

5.  Elevated Orai1 expression mediates tumor-promoting intracellular Ca2+ oscillations in human esophageal squamous cell carcinoma.

Authors:  Hua Zhu; Hui Zhang; Feng Jin; Mingzhu Fang; Mark Huang; Chung S Yang; Tong Chen; Liwu Fu; Zui Pan
Journal:  Oncotarget       Date:  2014-06-15

Review 6.  Advances in the study of cancer metastasis and calcium signaling as potential therapeutic targets.

Authors:  Chaochu Cui; Yongxi Zhang; Gang Liu; Shuhong Zhang; Jinghang Zhang; Xianwei Wang
Journal:  Explor Target Antitumor Ther       Date:  2021-06-28

7.  Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer.

Authors:  G Pelosi; U Pastorino; F Pasini; P Maissoneuve; F Fraggetta; A Iannucci; A Sonzogni; G De Manzoni; A Terzi; E Durante; E Bresaola; F Pezzella; G Viale
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.